CYP2A6基因型对胰腺导管腺癌围术期S-1治疗生存结局的影响
该回顾性研究纳入145例接受根治性切除及辅助S-1治疗的胰腺导管腺癌患者,其中78例接受含S-1新辅助治疗。全外显子测序检测CYP2A6变异,发现弱代谢型与更短的无复发性生存相关,且弱代谢型状态是总生存的独立不良预后因素。
要点
- CYP2A6功能减弱基因型在胰腺导管腺癌患者中占56.6%。
- 弱代谢型患者淋巴结转移频率更高(78.0% vs 52.4%)。
- 弱代谢型状态是总生存的独立不良预后因素(HR 3.17)。
核心结论
- CYP2A6功能减弱基因型与接受围术期S-1治疗的胰腺导管腺癌患者较差的肿瘤学结局相关。
- CYP2A6基因型可能作为优化治疗策略的生物标志物。
研究设计与样本
- 回顾性研究,纳入145例接受根治性切除和辅助S-1治疗的胰腺导管腺癌患者,其中78例接受含S-1新辅助治疗。
- 采用外周血全外显子测序鉴定胚系CYP2A6变异,将患者分为弱、中间和正常代谢组,使用Kaplan-Meier和Cox回归分析生存结局。
主要发现
- 82例(56.6%)患者携带功能减弱CYP2A6基因型,包括6例(4.1%)弱代谢型。
- 功能减弱基因型患者淋巴结转移频率更高(78.0% vs 52.4%,P=0.001)。
- 功能减弱基因型患者无复发生存显著更短(中位19.2 vs 32.3个月;P=0.040),总生存更短但无统计学显著性(47.9 vs 62.2个月;P=0.104)。
- 多变量分析中,CYP2A6弱代谢型状态与总生存独立相关(HR 3.17;95% CI 1.06-9.46;P=0.039)。
- 在78例接受含S-1新辅助治疗的患者中,功能减弱基因型患者的总生存和无复发生存均显著更差。
临床怎么用
- 对接受围术期S-1治疗的胰腺导管腺癌患者,可考虑检测CYP2A6基因型以识别弱代谢型高危人群。
- 弱代谢型患者可能需要更密切的随访或个体化治疗策略调整。
局限性
- 回顾性研究设计。
- 样本量有限(145例)。
- 研究人群为日本患者,CYP2A6变异频率可能与其他人群不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of CYP2A6 genetic polymorphisms on survival outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) receiving perioperative S-1 therapy. BACKGROUND: S-1, an oral fluoropyrimidine containing tegafur, is widely used for perioperative treatment of PDAC in Japan. Tegafur requires metabolic activation to 5-fluorouracil, primarily by CYP2A6. Given the high prevalence of reduced-function CYP2A6 variants in East Asian populations, their clinical significance in PDAC remains unclear. METHODS: This retrospective study included 145 patients with PDAC who underwent curative resection and received adjuvant S-1, including 78 patients who had received S-1-containing neoadjuvant therapy. Germline CYP2A6 variants were identified using whole-exome sequencing of peripheral blood samples. Decreased-function alleles (*4, *7, *9) and the rare nonsense allele *48 were evaluated. Patients were classified into poor, intermediate, and normal metabolizer groups. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses. RESULTS: Decreased-function CYP2A6 genotypes were identified in 82 patients (56.6%), including 6 poor metabolizers (4.1%). These patients had a higher frequency of lymph node metastasis than those with normal genotypes (78.0% vs. 52.4%, P=0.001). Recurrence-free survival (RFS) was significantly shorter (median, 19.2 vs. 32.3 mo; P=0.040), whereas overall survival (OS) was shorter but not statistically significant (47.9 vs. 62.2 mo; P=0.104). In multivariable analysis, CYP2A6 poor metabolizer status was independently associated with OS (HR, 3.17; 95% CI, 1.06-9.46; P=0.039). Among the 78 patients who received S-1-containing neoadjuvant therapy, both OS and RFS were significantly worse in those with decreased-function genotypes. CONCLUSIONS: Decreased CYP2A6 functional genotypes were associated with poorer oncological outcomes in patients with PDAC receiving perioperative S-1 therapy, suggesting that the CYP2A6 genotype may serve as a biomarker for optimizing treatment strategies.
引用
- Miura Y, Ohnami S, Ohshima K, et al. Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy. Ann Surg. 2026. PMID: 42475636. doi:10.1097/SLA.0000000000007152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。